IRF4 deficiency vulnerates B cell progeny for leukemogenesis via somatically acquired *Jak3* mutations conferring IL-7 hypersensitivity

Running title: IRF4 deficiency vulnerates preB cells for leukemogenesis

Dennis Das Gupta¹, Christoph Paul², Nadine Samel^{1,3}, Maria Bieringer¹, Daniel Staudenraus¹, Federico Marini⁴, Hartmann Raifer¹, Lisa Menke¹, Lea Hansal¹, Bärbel Camara¹, Edith Roth⁵, Patrick Daum⁵, Michael Wanzel⁶, Marco Mernberger^{6,7}, Andrea Nist⁶, Uta-Maria Bauer⁶, Frederik Helmprobst^{8,9}, Malte Buchholz¹⁰, Katrin Roth¹¹, Lorenz Bastian¹², Alina M Hartmann¹², Claudia Baldus¹², Koichi Ikuta¹³, Andreas Neubauer¹⁴, Andreas Burchert¹⁴, Hans-Martin Jäck⁵, Matthias Klein¹⁵, Tobias Bopp^{15,16}, Thorsten Stiewe^{6,7}, Axel Pagenstecher^{8,9}, Michael Lohoff¹

¹Institute for med. Microbiology & Hospital Hygiene, Philipps University Marburg, Germany

²University Hospital Gießen and Marburg, and Philipps University, Dept. Ophthalmology, *Marburg, Germany*

³3MVZ for Laboratory Medicine and Microbiology, Koblenz-Mittelrhein, Germany

⁴Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI), University Medical Center of the Johannes Gutenberg-University Mainz, Germany

⁵Division of Molecular Immunology, Nikolaus-Fiebiger Center, University of Erlangen-Nürnberg, Erlangen, Germany

⁶Institute for Molecular Biology and Tumor Research (IMT), Center for Tumor- and Immunobiology (ZTI), Philipps University Marburg, Germany

⁷Genomics Core Facility, Philipps University Marburg, Germany

⁸Core Facility for Mouse Pathology and Electron Microscopy, Philipps University Marburg, Germany

⁹University Hospital Gießen and Marburg, and Philipps University, Institute of Neuropathology, Marburg, Germany

¹⁰University Hospital Gießen and Marburg, and Philipps University, Clinic for Gastroenterology and Core Facility Small Animal Ultrasound, Marburg, Germany

¹¹Core facility for Cellular Imaging, Philipps University Marburg, Germany

¹²Medical Department II, Hematology and Oncology, University Medical Center Schleswig- Holstein, Kiel, Germany

¹³Institute for Frontier Life and Medical Sciences, Kyoto University, Japan

¹⁴University Hospital Gießen and Marburg, and Philipps University, Dept. Hematology, Oncology and Immunology, *Marburg, Germany*

¹⁵Institute for Immunology, Research Center for Immunotherapy (FZI), University Cancer Center, University Medical Center of the Johannes Gutenberg-University Mainz, Germany

¹⁶German Cancer Consortium (DKTK)

The authors have declared that no conflict of interest exists.

34 **Abstract**

35 The processes leading from disturbed B cell development to adult B cell progenitor acute
 36 lymphoblastic leukemia (BCP-ALL) are poorly understood. Here, we describe *Irf4*^{-/-} mice as
 37 prone to developing BCP-ALL with age. *Irf4*^{-/-} preB-I cells exhibited impaired differentiation but
 38 enhanced proliferation in response to IL-7, along with reduced retention in the IL-7 providing
 39 bone marrow niche due to decreased CXCL12 responsiveness. Thus selected, preB-I cells
 40 acquired *Jak3* mutations, probably following irregular AID activity, resulting in malignant
 41 transformation. We demonstrate heightened IL-7 sensitivity due to *Jak3* mutants, devise a
 42 model to explain it and describe structural and functional similarities to *Jak2* mutations often
 43 occurring in human Ph-like ALL. Finally, targeting JAK signaling with Ruxolitinib *in vivo*
 44 prolonged survival of mice bearing established *Irf4*^{-/-} leukemia. Intriguingly, organ infiltration
 45 including leukemic meningeosis was selectively reduced without affecting blood blast counts.
 46 In this work, we present spontaneous leukemogenesis following IRF4 deficiency with potential
 47 implications for high-risk BCP-ALL in adult humans.

48

49 Introduction

50 Two signaling pathways via the Interleukin-7 receptor (IL-7R) and the preB cell receptor
 51 (preBCR) ensure an orderly progression of B lymphopoiesis.¹⁻³ ProB cells adhere to bone
 52 marrow (BM) stromal cells (SCs) expressing CXCL12 and VCAM-1 through CXCR4 and VLA-
 53 4, respectively,⁴ while SC-derived IL-7 induces their proliferation.⁴ The formation of the preBCR
 54 composed of Ig μ protein and the surrogate light chain (ψ L), consisting of λ 5 and VPRED,
 55 marks the entrance to the preB cell stage. Signaling via the preBCR in turn induces the
 56 transcription factor (TF) interferon regulatory factor 4 (IRF4) which is also critical during T cell
 57 differentiation.^{5,6} In preB cells, IRF4 halts cycling and facilitates recombination of the light chain
 58 locus by RAG1/2.¹ Despite its importance, *Irf4*^{-/-} mice still develop, albeit less, surface (s)Ig μ ⁺
 59 mature B cells,⁷ likely due to a partially redundant function of IRF8. Accordingly, *Irf4,8*^{-/-} B
 60 progenitors are completely arrested at the preB cell stage.⁸

61
 62 Disruption of this developmental track can provoke B cell progenitor acute lymphoblastic
 63 leukemia (BCP-ALL). In humans, this disease preferentially affects children (age 0-19), while
 64 most deaths however occur in the adult population.⁹ Cases affecting adolescents and young
 65 adults (AYA) display a different set of driver mutations compared to childhood BCP-ALL.¹¹⁻¹⁴

66
 67 Herein, we report that adult *Irf4*^{-/-} mice spontaneously develop BCP-ALL with similarities to
 68 human AYA-BCP-ALL and delineate the steps from disturbed *Irf4*^{-/-} B lymphopoiesis to overt
 69 leukemia.

70

71 Results

72 *Irf4*^{-/-} mice spontaneously develop preB cell leukemia

73 Following the serendipitous finding, that some aged *Irf4*^{-/-} mice developed tumours and died,
74 we systematically observed 80 *Irf4*^{-/-} mice over time. We detected 14 tumours (incidence 17.5
75 %), that spontaneously appeared in lymph node (LN) areas (mean age: 268d, median: 238d,
76 Fig.1a). Tumours were neither detected in mice younger than 150d nor in C57BL/6 wild-type
77 (wt) mice housed in the same room.

78

79 All tumours (Fig.1b shows a representative tumour *in situ*) were accompanied by
80 lymphadenopathy (arrow heads) and increased spleen size (Fig.1c). Suspected
81 lymphomatous origin was corroborated microscopically (Fig.1b, right panels), with infiltration
82 of mononucleated cells into the BM, lung, and liver (Fig.1d). Due to the known impaired
83 maturation of *Irf4*^{-/-} preB cells,⁷ spontaneous eruption of preB-leukemia seemed plausible: In
84 spleen sections (Fig.1e), infiltrating cells stained positive for both B220 and Igμ (although less
85 than untransformed “follicle” B cells) and Ki67. By flow cytometry, BM samples from tumour
86 mice harboured an expanded pro/preB cell compartment (Hardy fraction (fr.)A-D,²¹
87 B220^{mid}sIgμ⁻) (Fig.1f-h). Fr.A-D cells were detected also in peripheral lymphoid organs and
88 blood of tumour mice (Fig.1h). Following the Hardy classification (Fig.1i), we determined
89 tumour cells to be fr.C preB cells (B220^{mid}sIgμ⁻CD43⁺CD24⁺BP-1⁺) (Fig.1j-k, sFig.1a). In
90 addition, Igμ, but not Igκ/λ was detected intracellularly (sFig.1b). Lastly, tumours stained
91 positive for surface λ5, part of the ψL (Fig.1l). These attributes characterize the disease as
92 preB-I cell BCP-ALL.

93

94 To prove clonality, we sequenced the VDJ junctions of the IgH region in three tumours
95 (supplementary Table 1). Almost all sequences per tumour were identical, demonstrating
96 clonality. The tumours (three examples) further displayed copy number variations (CNV)

(sFig.1h), targeting differing genomic regions. Finally, only 500 transferred tumour cells elicited leukemia in wt mice (sFig.1d-e), indicating *bona fide* malignancy.

99

B lymphopoiesis in *lrf4*^{-/-} mice harbours a hyperproliferative preB-I cell compartment.

The uniform appearance of BCP-ALL in *lrf4*^{-/-} mice suggested a defined preleukemic pro/preB cell state vulnerable to immortalization. Dimensional reduction of BM samples stained for B cell differentiation markers, identified an enlarged fr.C preB cell compartment already in healthy *lrf4*^{-/-} mice (Fig.2a-c). This disturbed, but productive B cell maturation confirms and extends previous reports.⁷ Expression analysis of IL-7Rα and of CD2 (sFig.2b-c), which accompanies cytosolic Igμ expression²² further showed an increased frequency of CD2^{-dim}IL-7Rα⁺B220⁺slgμ⁻ preB cells in *lrf4*^{-/-} mice.

108

Purified BM B220⁺ cells from *lrf4*^{-/-} and wt mice were cultured with IL-7 (Fig.2d-g) to compare proliferative capacities. After 6d, *lrf4*^{-/-} cells had expanded roughly three-fold, whereas wt cell numbers decreased. Phenotypically, *lrf4*^{-/-} cells expressed λ5 and accumulated at the fr.C stage (Fig.2e-f); exactly like *lrf4*^{-/-} leukemia (Fig.2g). In contrast, wt cells differentiated further, losing surface CD43 (fr.D) (Fig.2e-f) with some cells expressing slgμ (fr.E). Thus, IL-7 unmasked the leukemic potential of the fr.C compartment in *lrf4*^{-/-} mice with both unchecked proliferation and a reinforced differentiation block. Notably, IL-7 dependent *lrf4*^{-/-} preB-I cell proliferation was blocked by NIBR3049 and Ruxolitinib, inhibitors of the IL-7R downstream actors JAK3 and JAK1 respectively (sFig.2d).

118

***lrf4*^{-/-} B cell progenitor exhibit reduced retention to the BM niche**

As overt leukemia is characterized by systemic presence, we tested whether already preleukemic *lrf4*^{-/-} B cell progenitors would leak from the BM. To reduce the complex Hardy classification, we identified early B cell progenitors, approximately until the preB-I stage, by B220⁺CD2^{-dim} expression (sFig.2b). Accordingly, we detected higher frequencies of splenic

B220⁺CD2^{-dim} cells in *Ir4*^{-/-} than in wt mice (Fig.2h), which accumulated with age. Thus, premature BM evasion adds to the impaired differentiation and hyperproliferation that characterize *Ir4*^{-/-} preleukemia.

Potentially, this finding represented a systemic consequence of reduced vicinity to BM niche cells. We therefore analyzed proximity of *Ir4*^{-/-} and wt B220⁺CD2^{-dim} cells to IL-7⁺ BMSCs *in situ* using *Il7*^{EGFP} mice (Fig.2j-m, sFig.2e-f, supplementary movie 1).²³ In femur cryosections, the B220⁺CD2^{-dim} subset (Fig.2j, arrowheads) but not the whole *Ir4*^{-/-} B220⁺ cell compartment was on average located further away from IL-7⁺ BMSCs, compared to wt control (Fig.2l-m). We excluded differences in IL-7⁺ BMSC abundance between genotypes (sFig.2g).

B progenitor retention to BM is secured via interaction of CXCR4 on pro/preB cells with the IL-7⁺ BMSC-derived chemokine CXCL12.^{24,25} Notably, *Ir4*^{-/-} pro/preB cells expressed markedly lower levels of CXCR4 compared to wt cells (Fig.2n). Chemokine migration assays with Hardy fr.A-D cells showed that *Ir4*^{-/-} cells indeed migrated significantly less towards CXCL12 (Fig.2o). Thus, reduced CXCR4-CXCL12 interaction likely induces the systemic seeding of *Ir4*^{-/-} B progeny. Inversely, direct cell interactions are likely not responsible, because *Ir4*^{-/-} and wt fr.A-D cells adhered equally to monolayers of OP-9 cells *in vitro* (sFig.2h).

The IL-7-JAK-STAT-axis is recurrently altered in *Ir4*^{-/-} leukemia

Most likely, a second, acquired genetic alteration was necessary for *bona fide* leukemia development and arose with low frequency per time, explaining the affected age and relatively low penetrance. Importantly, IL-7 deprivation of BM-evaded pro/preB cells should create a strong survival stress and potential selection pressure for *bona fide* leukemogenesis. To identify somatically acquired mutations, we performed whole exome sequencing (WES) of three independent tumours (T8, T10, T11) compared to sorted B220⁺mIgM⁻ cells from *Ir4*^{-/-} BM. Comparisons of the single nucleotide variants (SNVs) between the three samples

identified nine genes affected in all three tumour samples (Fig.3a). Out of these, SNVs in four genes (*Rrs1*, *Jak3*, *AW82073* and *Duxf3*) showed alternate base frequencies close to 0.5 or 1 (Fig.3b), suggesting that they could be present on one or both alleles of all leukemic cells. Although we did not exclude oncogenic potential of the other three genes, we focused on *Jak3*, because it is associated with IL-7R signaling. We detected *Jak3* mutations also in tumours TD1, TD2 and T14 (Fig.3c, supplementary Table 2). Thus, six out of six tested tumours carried *Jak3* mutations (“JAK3_{mut}”). All mutations targeted either the active kinase domain or the pseudokinase domain regulating JAK3 activity. Some of these SNVs have been described before.²⁶ Further, using two different classifiers, no gene fusions could be detected (see methods). Analysis of typical BCP-ALL genes¹⁹ identified some respective mutations at low frequencies, indicative of subclonal events (Fig. 3d). Among these, mutations in *Jak1*, the partner to JAK3 in IL-7R signaling, were detected in both T8 and T11.

To analyze the role of the JAK3_{mut}, we transduced *Irf4*^{-/-} preB-I cell-cultures with retroviruses (RVs) encoding no or wt JAK3 or the JAK3_{mut} R653H and T844M. Culturing transduced cells in the presence of αIL-7 to test for IL-7 independency unexpectedly resulted in cell death after few days with no benefit for cells expressing JAK3_{mut} (sFig.3a-b). To test if JAK3_{mut} would confer advantages with limited IL-7, RV-infected *Irf4*^{-/-} preB-I cell-cultures were exposed to decreasing IL-7 concentrations (Fig.3e-g). At 0.1 and 0.01 ng/ml IL-7, both JAK3_{mut}⁺, but not JAK3_{wt}⁺-RV led to the outgrowth of transduced over untransduced cells after 6d of culture (Fig.3f-g). Thus, JAK3_{mut} confer IL-7-hypersensitivity, but not -independency. Accordingly, *ex vivo* cultured *Jak3*-mutated T8 and T11 cells also still depended on IL-7 (sFig.3c-d).

***Aicda* is upregulated in *Irf4*^{-/-} preB cells by LPS and deprivation of IL-7**

Because five out of six *Jak3* mutations were C to T base exchanges (Table 2), we suspected a specific mutagenic agent. DNA editing enzymes including the APOBEC family member AID³⁹ can deaminate cytosines, e.g. during somatic hypermutation.^{27,28} Repair mechanisms most

often ultimately cause C to T conversions.^{29,30} Notably, AID is induced in wt preB cells by IL-7 withdrawal and LPS stimulation and acts as a facilitator of human BCP-ALL.³¹ Therefore, we compared *Aicda* expression in sorted *Irf4*^{-/-} and wt fr.A-D cells to that of wt mesenteric (m)LN- and CD4⁺ T_H1-cells as controls and to individual leukemia samples. While mLN cells highly expressed *Aicda*, fr.A-D and leukemia-, but not T_H1-cells, also expressed readily detectable amounts (Fig.3h).

Furthermore, like their wt counterpart,³¹ *in vitro* expanded *Irf4*^{-/-} preB-I cells upregulated *Aicda* further under LPS treatment and during IL-7 withdrawal (Fig.3i). This finding can explain how BM evasion and exposure to pathogens might cooperatively initiate mutagenic processes via AID in vulnerable *Irf4*^{-/-} preB-I cells.

To test if T8 exhibited signs of previous AID activity on a global level, we analyzed C:T/G:A-transition frequencies in WES of T8, as well as BM-sorted *Irf4*^{-/-} and wt fr.A-D cells compared with matched tail-tip samples. Indeed, we found a marked preponderance of C:T/G:A-transitions in T8, when filtering on putative somatic core SNVs (Fig.3j).

***Jak3* mutations in mice mirror *Jak2* mutations in human Ph-like ALL**

Next, we compared *Irf4*^{-/-} leukemia to the complex landscape of human BCP-ALL subtypes (reviewed in refs. ^{12,32,33}), using a published human BCP-ALL cohort for which a random forest classifier had been established (Methods for details).³⁴ Only mildly (potentially due to the interspecies comparison) elevated prediction scores were generated for Ph⁺, Ph-like, KMT2a- and DUX4-rearranged human BCP-ALL (sFig.4a-b). Since all of these except Ph-like are defined by specific gene rearrangements, that we had not detected in *Irf4*^{-/-} mouse leukemia, we excluded them as comparable candidates.

204 Ph-like ALL harbours recurrent genetic alterations in signaling molecules, especially in CRLF2
205 and JAK2.¹⁹ While BCP-ALL overall preferentially affects children, the incidence of the Ph-like
206 subtype increases from 10 % in children to above 25 % in AYA and adults,^{19,35} reminiscent of
207 the older age of *Irf4*^{-/-} leukemic mice. Furthermore, a published dataset of 154 Ph-like BCP-
208 ALL cases exhibited 10-fold reduced *IRF4* transcripts, when compared to other BCP-ALL
209 subtypes.¹⁹

210

211 While in human Ph-like ALL *Jak2* is commonly mutated, we report recurrent *Jak3* mutations in
212 *Irf4*^{-/-} mice. As both proteins are part of distinct but similar signaling complexes in B cell
213 progenitors (Fig.4a), we investigated structural and functional similarities between the specific
214 *Jak3* and *Jak2* mutations. Comparisons of amino-acid-sequences revealed high protein-wide
215 interspecies and intermolecular similarities for both proteins (Fig.4b). Mapping the two amino
216 acids R653 and T844 (mutated in *Irf4*^{-/-} mice) onto JAK3 structure predictions, generated by
217 the alpha-fold-algorithm,³⁶ revealed that the two amino-acids are in direct contact at an
218 interface of JH1-JH2 domains (Fig.4c). This interface specifically is highly conserved in JAK2
219 compared to JAK3 (Fig.4d-f, sFig.4c-d). Intriguingly, R683 (corresponding to R653 in JAK3) is
220 by far the most commonly mutated amino-acid in JAK2 in Ph-like ALL, while mutations
221 targeting T875 (corresponding to T844) also have been described.³⁷ These findings suggest
222 that mutations in human JAK2 and mouse JAK3 affect a highly similar functional hotspot.

223

224 As mentioned above, JAK2 and JAK3 are part of distinct, but similar receptors: JAK3 binds the
225 common γ -chain involved in IL-7 signaling, while JAK2 associates with CRLF2 involved in
226 TSLP signaling. Both signals involve the IL-7R α chain and the same downstream pathways
227 (STATs, PI3K).³⁸ Therefore, alternative presence of JAK3/JAK2 mutations between mouse
228 and human BCP-ALL might reflect different cytokine preferences. Human proB/preB cells
229 proliferate in response to both TSLP and IL-7.³⁹ However, in *Irf4*^{-/-} BM cells IL-7, but not TSLP

induced robust proliferation (Fig.4g) as well as high frequencies and absolute counts of CD43⁺ (Fig.4h) and λ5⁺ preB cells (Fig.4i-j).

IRF4 re-expression leads to cell death and differentiation

As *Irf4* deletion was a prerequisite for leukemia in our model, we examined the effect of forced IRF4 re-expression, using RVs coding for GFP alone (EV-RV) or plus IRF4 (IRF4-RV). When re-introducing IRF4 into T8 or T11, GFP⁺ IRF4-expressing-, but not GFP⁺ control-cells gradually disappeared over time (Fig.5a). AnnexinV/PI stainings confirmed apoptosis (not shown). Further, we noted loss of surface λ5-expression induced by IRF4-RV (Fig.5b-c). Comparing the transcriptomes of still viable cells 24h after transduction revealed strong induction of “apoptotic process” and “innate immune response” gene ontology (GO) gene sets (gs) (Fig.5d). Markov clustering of GO gs affected by IRF4 re-expression (Fig.5e-f) further identified several coregulated B cell differentiation gs (Fig.5f), with downregulated ψL components *Igll1*, *Vpreb1* and *Vpreb2*, but upregulated differentiation genes including *Igμ*, *Igκ* and *Blnk* (Fig.5g-h, sFig.5a-b). Similar results were obtained for T11 (sFig.5c-d). Therefore, fully transformed leukemia remained targetable by IRF4 re-expression.

Small compound agents affecting *Irf4*^{-/-} leukemia cells in vitro

Next, we screened a collection of kinase inhibitors for their capacity to kill *Irf4*^{-/-} leukemia cells *in vitro*. We included NIBR3049 targeting JAK3, Ruxolitinib, an inhibitor of JAK1/2 (downstream of JAK3) and Dexamethasone, a cornerstone for treating lymphomatous malignancies. Furthermore, we included inhibitors of NFκB (IKK, TAK1), JNK, MEK, ERK, PP2A, GFI1, FAK and of the Bruton tyrosine kinase (BTK) acting downstream of the BCR.

A variety of these substances potently killed tumour cells (sFig.6a), implying involvement of multiple pathways in leukemia cell survival. Efficacy of Ruxolitinib and NIBR3049 corroborated

our results concerning *Jak3* driver mutations. Furthermore, inhibitors of GFI1 and PP2A as well as NFκB and JNK were potent. In contrast, inhibiting BTK, MEK and ERK had no impact.⁴⁰

***In vivo* therapy of established *Irf4*^{-/-} B-ALL**

Next, we implemented JAK inhibition as *in vivo* treatment for *Irf4*^{-/-} leukemia. We began induction therapy with Dexamethasone around day 12 after adoptively transferring 3x10⁵ T8.1 cells *i.p.* into wt mice (Fig.6a), when overt leukemia was noted in peripheral blood (pB) (Fig.6b “pre”). After 7d of treatment, leukemic cell numbers in pB were robustly reduced (Fig.6b “post”), although few cells reproducibly remained detectable (Fig.6c). Maintenance therapy was continued with Ruxolitinib or vehicle control by oral gavage twice daily for the following 12 days (Fig.6a,c). Importantly, the half-life of Ruxolitinib in mice is only 0.8 h (“Australian Public Assessment Report for Ruxolitinib”, Australian Government), implying that any observed *in vivo* effectiveness might be underestimated.

Despite maintenance therapy, leukemic cells in pB reappeared, with no significant difference between treatment groups (Fig.6c). However, treatment with Ruxolitinib resulted in a clear survival benefit (Fig.6d) and marked improvement of a prominent neurological symptom: in sham-treated animals, temporary limpness of tail and hind legs occurred seconds after gavage, which we quantified using a newly established scoring system (ranging from 0 to 3, see Methods).

Mechanistically, ultrasound revealed an echogenic paravertebral mass (sFig.7a-b) in score 3, but not score 0 mice. By histology, score 3 correlated with severe infiltration of blasts into the spinal canal (X in Fig.6f), extending into spinal nerve roots (arrowhead in Fig.6f). Therefore, paraparesis likely represented a manifestation of mouse leukemic meningeosis, exacerbated by gavage-induced increases in intraabdominal pressure.

Paraparesis was reproducibly relieved during Ruxolitinib treatment (Fig.6e), correlating with the suppression of perimyeloid infiltration that ensued in vehicle-treated mice after the end of induction therapy (Fig.6h). In contrast, the severely impaired hematopoiesis in sham-treated mice, indicated by low CAE⁺ cell frequencies, was not significantly ameliorated by Ruxolitinib (Fig. 6i-j).

These findings raised the possibility that Ruxolitinib preferentially targets infiltration of solid organs rather than BM or pB. Accordingly, Ruxolitinib fully blocked the liver infiltration as observed in sham-treated mice (Fig.6k-l). As tissue infiltration is regulated by homing receptors, we treated T8.1 and T8.2 cells with Ruxolitinib *in vitro* and recorded the expression of CD29 (integrin $\beta 1$), which pairs with various integrin alpha chains involved in cell- and tissue-adhesion.^{41,42} Notably, on T8.1 and T8.2, Ruxolitinib reduced CD29 expression dose-dependently (sFig.6c-e) while even slightly increasing expression of MHC I molecules (H2D^b, H2K^b), stained as specificity control.

Discussion

The herein described spontaneous leukemogenesis in *Irf4*^{-/-} mouse stresses the particular vulnerability of preB-I cells. Our data provides insights for a.) conditions promoting leukemogenesis, b.) functional consequences of *Jak* mutations, c.) parallels of mouse and human BCP-ALL and d.) potential *in vivo* treatment:

a.) We provide evidence for a two-hit leukemogenesis model: The first hit (*Irf4* loss) resulted in reduced differentiation, IL-7 dependent hyperproliferation and impaired retention to the BM niche (Fig.7). A second hit (targeting *Jak3* in our model) created a dominant survival signal, resulting in overt preB-I leukemia.

309 The induction of BCP-ALL in *Irf4*^{-/-} mice is similar to *Ikzf1* and *Pax5* mutated mouse models,⁴³⁻
 310 ⁴⁵ implying similarities between these TF-alterations. Probably, one shared mechanism is the
 311 differentiative impairment. Importantly, for *Irf4*^{-/-} fr.A-D cells we even detect slightly higher
 312 levels of *Pax5* compared to wt fr.A-D cells (sFig.8), ruling out that the findings in *Irf4*^{-/-} mice
 313 merely mirror those of *Pax5* deficiency. The reverse remains conceivable; that *Ikzf1* and *Pax5*
 314 mutations converge lowering IRF4 expression.

315

316 In addition to mice mutated in *Pax5* or *Ikzf1*, *Irf4/Irf8*^{-/-} and *Irf4/Spi1*^{-/-} mice have been shown
 317 to develop leukemia early in life at high incidence.^{20,46} Contrasting these studies, we report that
 318 single deficiency for IRF4 fully suffices for leukemogenesis. We excluded secondary
 319 alterations in *Irf8*, *Spi1* in our model: we found unchanged expression and gene sequence of
 320 IRF8 (not shown) and normal amounts of *Spi1* transcripts (sFig.8a) in *Irf4*^{-/-} fr.A-D cells. The
 321 single IRF4 deficiency models potential clonal initiating events better than *Irf4/Irf8*^{-/-} or
 322 *Irf4/Spi1*^{-/-} mice, because *Irf4*^{-/-} mice harbour productive B cell development.

323

324 We newly describe that a preleukemic alteration can lead to reduced BM retention, presenting
 325 a tentative explanation for the induction of mutagenic signals, as deprivation from IL-7 and
 326 exposure to bacterial compounds can cooperatively induce the mutagenic agent AID.³¹

327

328 b.) Why do *Jak3* mutations only lead to enhanced sensitivity to, but not complete independence
 329 of IL-7? Analysis of JAK3 and JAK2 structure implied that mutations of R683/R653 and
 330 T875/T844 might decrease JH1-JH2 interaction strength. This would imply reduced auto-
 331 inhibition as the GOF mechanism – in line with findings for the JAK family member TYK2.⁴⁸
 332 This alone cannot explain cytokine independency, owing to the receptor biology: The two
 333 preassembled receptor-chains keep JAKs intracellularly separated.⁴⁹ Ligand binding is needed
 334 for a conformational change that brings JAKs into the proximity needed for cross-
 335 phosphorylation.

336

337 To explain our observations, we propose an oncogene model with two equilibria (Fig.8a-b):
 338 the first is determined by cytokine concentration and dictates the probability of receptor
 339 conformation change (Fig.8a). The second, independent equilibrium (Fig.8b), is determined by
 340 the interaction strength at the JH1-JH2 interface and dictates the probability of JH1 and JH2
 341 dissociation. Only the combination of the “bound” and “active” state (Fig.8c) would result in the
 342 elicitation of a signal (Fig.8c, green frame).

343

344 In this model, JAK mutations would only affect the second equilibrium (Fig.8d, red arrows).
 345 Therefore, sporadic ligand binding would still be needed for elicitation of signaling. The model
 346 stringently predicts the better exploitation of low cytokine concentrations for JAK_{mut} that we
 347 observed *in vitro*. Fig.8d depicts theoretical probabilities of receptor states for varying cytokine
 348 concentrations in the presence (top row) or absence (bottom row) of JAK mutations.

349

350 Our findings that JAK3_{mut} confer heightened cytokine-sensitivity, but not -independence, is in
 351 contrast to what has been found for JAK2-R683G mutants expressed in the commonly used
 352 BaF3 cell-line.⁵¹ However, BaF3 cells depend on IL-3 and not IL-7R α cytokines (i.e. IL-7 or
 353 TSLP). Therefore, it remains conceivable, that the IL-3 receptor provides a different
 354 physiology, which may deviate from the IL-7R physiology in primary B progenitors.

355

356 c.) The finding that *Irf4*^{-/-} preB-I cells respond preferentially to IL-7 over TSLP presents a
 357 possible explanation, why mouse models of BCP-ALL acquire *Jak3* mutations, whereas the
 358 human Ph-like disease typically harbours *Jak2* mutations. Our comparison of JAK structure
 359 predictions yielded corresponding mutations likely to elicit similar downstream effects.

360

361 d.) Lastly, our *in vivo* experiments reinforce Ruxolitinib as a potential treatment for JAK driven
 362 BCP-ALL. The compound represents an important therapeutic agent in myeloproliferative

363 disease and is already studied for treatment of Ph-like-ALL.^{52,53} We describe a preferential
 364 effect of Ruxolitinib on CNS- and organ infiltration, potentially due to reductions in integrin
 365 expression on leukemia cells. These effects are of translational importance because current
 366 CNS-targeted therapies for ALL remain toxic. Future studies should therefore evaluate efficacy
 367 of Ruxolitinib for leukemic organ infiltration in other leukemia models.
 368

369 **Methods**

370 **Mice**

371 C57Bl/6 mice were purchased from Charles River, Sulzfeld, Germany. *Irf4*^{-/-} mice⁷ and *Il7*^{eGFP}
372 mice⁵⁵ (provided by Koji Tokoyoda, DRFZ Berlin) were bred on the C57Bl/6 background and
373 housed in the animal facility of the Biomedical Research Center at the university of Marburg,
374 Germany. If not stated otherwise, all mice used in the presented experiments were 8-12 weeks
375 old and sex-matched.

376

377 **Tumor cell lines and cell culture**

378 Stable tumor cell lines T8.1, T8.2 and T11 were established from primary *Irf4*^{-/-} leukemia cells
379 (derived from primary tumour 8, i.e. T8, or tumour 11) by culturing them on a monolayer of
380 irradiated (30 Gy) ST2 stromal cells⁵⁶ grown to confluency in Opti-MEM medium (31985070,
381 ThermoFisher Scientific) supplied with 1 % cell culture supernatant from JIL-7.6 J558 cells⁵⁷
382 (a gift from Fritz Melchers, Berlin) as a source of IL-7. After several passages, T8 and T11
383 cells grew independently of ST-2 cells. For *in vitro* inhibitor experiments, 2.5 x 10⁵ T8.1 or T8.2
384 cells (or T11 cells) were cultured in 500 μ L RPMI medium in 48 well plates in the presence of
385 the indicated concentrations of inhibitors. To determine the percentage of viable cells, samples
386 were stained using Annexin V and propidium iodide (PI) (see below) after 48 h. Substances
387 used include: Defactinib (S7654, Selleckchem), Oxocaenol (O9890, Sigma), GANT61 (Sigma,
388 G9048), SP203580 (EI-286-0001, Enzo), SP600125 (EI-305-0010, Enzo), PD98059,
389 Promega), Ibrutinib (S2680, Selleckchem), BAY11-7082 (ALX-270-219, Alexis),
390 Dexamethasone (PZN 08704491, mibe GmbH) and Ocadaic acid (O4511, Sigma).

391

392 **Murine pro/preB cell cultures**

393 Femur and tibia bones from 8-12 weeks old mice were explanted and cleaned from adherent
394 tissues. Cells were extracted via centrifugation at 11 x 10³ RPM for 10 s. Total BM cells were
395 enriched for B220⁺ (slg μ ⁻) B lineage cells using an inhouse magnetic activated cell sorting

396 protocol. Briefly, whole bone marrow cells were stained with a mix of FITC-conjugated
397 antibodies to (Ig μ), CD11b, B220, Ter119, CD49b, CD4 and CD8 (all from eBioscience),
398 followed by incubation with an anti FITC/streptavidin/biotin/magnetic bead complex (Miltenyi
399 Biotec) and magnetic sorting using a microcentrifugation tube stand (Miltenyi Biotec).⁵⁸ Sorting
400 efficiency, as confirmed by flow cytometry, routinely exceeded 90 %. Cells were seeded at a
401 density of 1×10^5 cells per well in 200 μ L RPMI complete (96-well plates, Greiner). Pro/preB
402 cell cultures were propagated with 10 ng/mL rmlL-7 (217-17, Peprotech) in RPMI-1640
403 medium complete (R8758, Sigma-Aldrich, supplemented with: 10% FCS (Sigma-Aldrich),
404 2mM L-glutamine (Biochrom), 50 μ M β -mercaptoethanol (Sigma-Aldrich), 0,03/0,05 g per 500
405 mL Penicillin G/Streptomycin Sulfate, 1 % non-essential amino acids (PAA Laboratories)). In
406 some experiments, pro/preB cells (1.25×10^6 /mL medium) were treated for 24 h with LPS
407 (Sigma, 1 μ g/ml), anti-IL-7 (BioXCell, 10 μ g/ml), rmlL-7 or respective combinations, before
408 generating mRNA for qRT-PCR.

409

410 **Transwell migration assay and OP-9 adhesion assay**

411 For transwell migration assay, Hardy fr.A-D cells were magnetically sorted from BM of wt and
412 *Irf4*^{-/-} mice as described above (with addition of FITC-conjugated anti-Ig μ antibody), and $2 \times$
413 10^5 cells in RPMI (without additives, FCS-free) 10 ng/mL rmlL-7 seeded in 50 μ L in the top
414 chamber of 96 well 5 μ m pore uncoated 96 well transwell plates (HTS transwell® Corning). The
415 bottom chamber was flooded with 200 μ L RPMI containing indicated concentrations of
416 rmCXCL12 (Peprotech). After 16 h, inserts were removed, cells in the bottom chamber
417 collected, counted and analyzed for B220 surface expression using flow cytometry. The
418 fraction of migrated cells was calculated as $n(\text{migrated}) * \text{freq}_{\text{B220}}(\text{migrated}) / n(\text{input}) * \text{freq}_{\text{B220}}(\text{input})$. Normalization to B220⁺ cells reduced interexperimental differences due to
419 differences in cell purity after magnetic selection. For OP-9 adhesion assays, 5×10^3 OP-9
420 cells (a gift from Hyun-Dong Chang, DRZF Berlin) were seeded in 96 well microtiter plates 24
421 h before the assay. At the day of the assay, fr.A-D cells were purified as above and 2×10^5
422

fr.A-D cells seeded on top of OP-9 monolayers in RPMI complete + 10 ng/mL rmlL-7. Plates were centrifuged briefly to accelerate cell descension. After 1 h, suspended cells were collected in the supernatant and by washing OP-9 monolayers two times with PBS.

Flow cytometry and cell sorting

For surface staining of B lineage markers, cells were harvested, resuspended in PBS/1% FCS and stained with anti-B220 (RA3-6B2, Biolegend), anti-Ig μ (II/41, BD Bioscience), anti-CD43 (RM2-5, Biolegend), anti-CD24 (M1/69, invitrogen), anti-BP-1 (BP-1, BD Bioscience), anti-CD2 (RM2-5, Biolegend), anti-CXCR4 (L276F12, Biolegend), anti-CD127 (=IL-7R α) (A7R34, BD Bioscience), anti-CD179b (=λ5) (LM34, BD Bioscience) as indicated (20 min at room temperature in the dark). All antibodies were employed at a dilution of 1:500. Fluorescence was recorded using either a FACS Aria III (BD) or an Attune NxT (Thermo-Fisher) analyzer. Data analysis was performed using the FlowJo V10 software (BD). For dimensional reduction we used the t-Distributed Stochastic Neighbor Embedding (t-SNE)⁵⁹ algorithm built into FlowJo V10. Epitopes on BM cells from *Irf4*^{-/-} and wt control mice used for dimensional reduction analysis comprised B220, slg μ , CD43, CD24, BP-1. For RNA and WES analyses, BM cells were surface labeled for B220 and slg μ expression and B220⁺slg μ ⁻ cells were sorted using a FACS Aria III (BD Bioscience). Sorting efficiency was routinely above 95 %. To determine cell viability, AnnexinV/propidium iodide (PI) staining was performed using 5 μ L AnnexinV (640905, Biolegend) per 500 μ L HBSS. After 20 min of incubation at room temperature in the dark, 1 μ L propidium iodide (421301, Biolegend) was added and cells were immediately measured.

Copy number variations (CNVs) analysis

CNVs were analyzed in tumour samples 8, 10 and 14 and compared to *Irf4*^{-/-} normal tail tissue. Whole DNA was extracted from 5 x 10⁶ cells per sample using the Macherey-Nagel NucleoSpin Tissue kit (REF 740952.50) according to the manufacturer's protocol. Library preparation was performed using the Illumina Nextera DNA kit according to manufacturer's

instruction. Sequencing was performed on an Illumina-HiSeq-1500 platform in rapid-run mode at the Genomics Core Facility of Philipps-University Marburg. Fastq quality control was performed using custom scripts. Raw sequenced reads were aligned to the Ensembl Mus musculus reference (revision 79) using Bowtie2 (version 2.0.0)⁶⁰ with standard parametrization. Analysis of CNVs was performed using the cn.mops (Copy Number estimation by a Mixture Of PoissonS) package (version 1.18.1)⁶¹ with the following parametrization: prior impact = 1, lower threshold -0.9, upper threshold = 0.5 minimum width = 4. Window length was set to 10000 and the algorithm was run in unpaired mode.

BM cryosections and analysis of B progenitor vicinity to IL-7⁺ BMSCs

Mouse femora from *Irf4*^{-/-} or *wt il7^{eGFP}* reporter mice were explanted, cleaned from soft tissues and fixated over-night in 4 % PFA PBS (Alfa Aesar). Samples were then dehydrated by incubation in 30 % sucrose in PBS for 24 h. Dried and dehydrated femora were snap frozen in cryomolds® (Tissue-Tek) using O.C.T freezing medium (Tissue-Tek) by being placed in a beaker of Hexan, surrounded by a beaker of Acetone and dry-ice. Samples were stored at -20°C until processing. Cryosections of 7 µm were generated with a Leica cryostat (DB80 LX microtome blades, Leica) using Kawamoto tape⁶² (Section-lab) as described before.⁶³ Cryosections were stained with antibodies against B220 (RA3-6B2, Biolegend), CD2 (14-0021-85, eBioscience, conjugated to AF555 using lightning-Link kit, abcam), GFP (Rockland goat polyclonal anti-GFP, 600-101-215) with secondary rabbit anti-goat F(ab')₂ AF488 (thermo-scientific A21222). Samples were then mounted in DAPI ProLong Gold Antifade (ThermoFisher Scientific). Images were recorded using a Leica confocal (SP8i) microscope. Image analysis was performed in IMARIS (version 9.7.2).

Histological analyses

Tissue samples were immediately fixed in 4 % PFA PBS solution. Histological analysis was performed on 3 µm thick sections from paraffin embedded tissue as described previously.⁶⁴

477 Briefly, rehydrated paraffin sections were first blocked with 0.3 % H₂O₂ and goat normal serum.
 478 For immunohistochemical (IHC) stainings, rat antibodies against CD45R/B220 (clone RA3-
 479 6B2, BD) and KI67 (clone TEC-3, Dako) were then incubated on the tissue slices and bound
 480 antibody was detected with biotinylated goat anti-rat IgG (Southern Biotechnology). Bound
 481 antibody was visualized with the Vectastain-kit (Vector Laboratories) according to the
 482 manufacturer's protocol. Hematoxylin-Eosin (HE) stainings were performed according to
 483 standard procedures. Cells of the granulocytic lineage were stained on paraffin embedded
 484 tissues with the Napthol AS-D Chloracetate (Specific Esterase, CAE) Kit (Ref: 91C-1KT,
 485 Sigma-Aldrich) according to the manufacturers protocol.
 486 In the *in vivo* therapeutic experiments, we calculated the narrowing of the spinal cord using the
 487 equation $A_t/(A_{sca}-A_{sp})$, where A_{sca} is the area of the spinal canal, A_t that of the tumor and A_{sp}
 488 that of the spinal cord area. Two different cross sections per animal were examined. The
 489 infiltration of the liver was calculated by dividing the tumor area in the liver by the whole area
 490 of the liver section. Three whole liver sections were analyzed per animal. All measurements
 491 were performed using Fiji.⁶⁵

492

493 **Whole Exome Sequencing and biostatistical analysis**

494 To determine single nucleotide variants (SNV) within leukemia samples, genomic (g)DNA was
 495 extracted both from primary *Irf4*^{-/-} tumours as well as FACS-sorted control B220⁺mIgM⁺ BM
 496 fr.A-D cells using the High Pure PCR Template Preparation kit from Roche (11796828001).
 497 Integrity of resultant gDNA was confirmed in a 2 % Agarose gel. MacroGen in Seoul performed
 498 SureSelect All Exon V6 library preparation and sequenced exons on a NovaSeq platform
 499 producing 2 x 150 bp reads at a coverage of 100x (50x on-target coverage). Fastq quality
 500 control was performed using FASTQC (version 0.11.9). Raw sequenced reads were aligned
 501 to the Ensembl Mus musculus reference (revision 96) using STAR (version 2.6.1d) using
 502 default parametrization. Soft-clipped aligned reads were then subjected to variant calling
 503 analysis. Position-wise pile-up files were generated using samtools (version 1.9) with the

mpileup option and a pileup quality threshold of 15, both for single sample and matched variant calling. Subsequently, variant calling was performed for SNP and InDel detection using VarScan2 (version 2.3.9) on single samples with the following parametrization: sampling depth = 100000, minimum variant frequency = 0.05, minimum coverage = 8, minimum variant reads = 2, minimum average read quality = 15 and a p-value threshold was set to 0.05. Only primary alignments were considered, the strand filter was enabled, and duplicates were removed. As a comparison, matched tumour-normal variant calling was performed with VarScan as well using identical parameter setting with the somatic p-value threshold set to 0.05.

For Fig.3n raw sequenced reads were aligned to the Ensembl Mus musculus reference (revision 96) using Burrows-Wheeler Aligner (BWA version 0.7.17) using default parametrization.⁶⁶ Prior to variant calling, aligned reads were filtered using a custom filter that excludes reads with more than 3 mismatches, more than 2 indels or a mapping quality below 20 using pysam (version 0.16.0.1). Duplicates were marked and removed using Picard (GATK version 4.1.6.0).⁶⁷ Filtered aligned reads were then subjected to variant calling analysis. Position-wise pile-up files were generated using samtools (version 1.9) with the mpileup option and a minimal base quality threshold of 20. Subsequently, variant calling performed for SNP detection using VarScan2 (version 2.4.4) using matched tumor-normal (somatic) mode with the following parametrization: sampling depth = 100000, minimum variant frequency = 0.2, minimum coverage = 8, minimum variant supporting reads = 5, minimum average read quality = 20 and a somatic p-value threshold was set to 0.05. Only primary alignments were considered, the strand filter was enabled. SNP calls were filtered to high confidence somatic mutations using VarScan's somaticFilter method, SNPs with a variant allele frequency above 0 in the matched reference sample were excluded.

527

528 **Sanger Sequencing and polymerase chain reaction**

529 SNVs in the JAK3 gene were confirmed by Sanger sequencing of PCR fragments spanning
530 the *Jak3* pseudokinase and kinase region (primers used for PCR amplification and Sanger

Sequencing: mJAK3 for, mJAK3 rev s. supplemental data). Sequencing services were provided by Microsynth SeqLab. To determine clonality of tumour cells, the V μ H region was amplified by PCR. Amplicons were run on an agarose gel and extracted using the QIAquick Gel Extraction Kit (Qiagen). DNA fragments were then cloned into the vector pJet1.2 (Thermo Scientific) and transformed into DH10B E. coli. The indicated numbers of clones (Fig. 1G) for each PCR amplicon were sequenced and aligned with software from IMGT/V-quest.⁶⁸

Retroviral transduction of *Jak3*-mutants and IL-7 independency assay

The coding sequence of murine *Jak3* was amplified from pCineo-Jak3 (a gift from Olli Silvennoinen from Tampere-university in Finland) and cloned into the pMSCV-Thy1.1 expression plasmid using *Bam*HI and *Sal*I restriction digestion. Site directed mutagenesis was performed following the manufacturer's protocol using the Quick-Change II site-directed mutagenesis kit (Agilent Technologies; primers employed are listed in the supplemental materials). Viral supernatant from mutated pMSCV-Thy1.1-Jak3 constructs was produced as described previously.⁵⁸ For viral transduction, 5 x 10⁵ IL-7 dependent primary *lrf4*^{-/-} preB-I cell cultures were resuspended in 400 μ L RPMI medium (D5030, Sigma-Aldrich) with 600 μ L viral supernatant and 1.5 μ L polybrene and spun in culture plates at 2700 RPM for 90 min at 37 °C. Cells were then replenished with conditioned medium and rested for 24 h. Transduction efficiency was measured by flow cytometry using surface staining for Thy1.1 (OX-70, Biolegend). For the IL-7 independency assay (Fig. 3 B), transduced cells were split and cultured with either recombinant murine (rm)IL-7 or 10 μ g/ml neutralizing anti-IL-7 antibody (BE0048, Bio X Cell). Same protocol applied for STAT5_{ca}-RV transduction. The STAT5_{ca}-construct had been generated by EcoRI excision of STAT5A1*6 from pMSCV-STAT5A1*6-NGFR⁶⁹ and insertion into the pMIG expression plasmid.

557 **RNA sequencing and biostatistical analysis**

558 RNA extraction from primary tumour samples and FACS sorted B220⁺ mIgM⁺ pro/preB cells
 559 was performed using Trizol extraction. Quality control was performed using the Bioanalyzer
 560 RNA 6000 NanoChip (Agilent Technologies). Library preparation was performed at the Institute
 561 for Immunology, University Medical Center of the Johannes Gutenberg-University Mainz using
 562 the NEBNext Ultra Library Prep kit (New England Biolabs). For deep sequencing, the Illumina-
 563 HiSeq- 4000 platform was used (Beijing Genomic Institute). Quality control on the sequencing
 564 data was performed with the FastQC tool (version 0.11.2,
 565 <https://www.bioinformatics.babraham.ac.uk/projects/fastqc/>). RNA sequencing reads were
 566 aligned to the ENSEMBL Mus_musculus.GRCm38 reference genome. The corresponding
 567 annotation (ENSEMBL v76) was also retrieved from ENSEMBL FTP website. The STAR
 568 aligner (version 2.4.0j) was used to perform mapping to the reference genome. Alignments
 569 were processed with the featureCounts function⁷⁰ of the Rsubread package, using the
 570 annotation file also used for supporting the alignment. Exploratory Data Analysis was
 571 performed with the pcaExplorer package.⁷¹ Differential expression analysis was performed
 572 with DESeq2 package,⁷² setting the false discovery rate (FDR) cutoff to 0.1. DESeq2 datasets
 573 were analyzed using the GeneTonic⁷³ and pcaExplorer packages. To assess the possible
 574 occurrence of gene fusions, we applied two different methods, Star-Fusion (version 1.10.1)
 575 and Arriba (version 2.1.0). For STAR Fusion, required meta reference files were created from
 576 the Ensembl Mus musculus reference (revision 100) as recommended in the STAR Fusion
 577 manual. In case of Arriba, we used the mm10+GENCODEM25 assembly. In each case, we
 578 used the dockerized versions of the tools. Raw fastq files were used as an input for both tools.
 579 Subsequently, raw reads were mapped using the recommended alternative STAR settings
 580 recommended in the tools manual to leverage chimeric reads from the alignments. Default
 581 filters as recommended by the STAR-Fusion and Arriba manuals were applied to limit the false-
 582 positive rate. For the same reason, known blacklisted regions as provided by the Arriba release
 583 were excluded from the analysis.

BCP-ALL subtype predictions using random forest classifier

Human genes (GRCh38.p13, v104) with annotated orthologous genes in mouse were extracted from ensembl database using the BiomaRt online tool. Gene counts from RNA-sequencing of a previously published human BCP-ALL cohort³⁴ and of murine tumor samples were subsetting to include only human-mouse orthologous genes. Resulting gene counts were normalized by variant stabilisation transformation using the R package DESeq2 version 1.32.0. Allocation of the murine tumor samples to human BCP-ALL molecular subtypes were performed based on gene expression using a random forest machine learning algorithm (R package caret version 6.0-88) trained on the human cohort. Predictions were plotted using R package pheatmap version 1.0.12. Differential gene expression was analyzed in R package DESeq2 and resulting gene lists ranked by log2-fold-change were analyzed in GSEA version 4.1.0.

JAK structure and sequence analysis

Mouse JAK2 (AF-Q62120) and JAK3 (AF-Q62137) structure predictions were acquired from the AlphaFold protein structure database⁷⁴ and visualized in UCSF ChimeraX (version 1.2.5).⁷⁵ Multiple sequence alignments were performed using the EMBL-EBI Clustal Omega tool.

Quantitative real time (qRT-)PCR

Total RNA was extracted both from primary *Irf4*^{-/-} tumors as well as FACS-sorted control B220⁺sIgμ⁻ BM fr.A-D cells of either *Irf4*^{-/-} or wt animals using the Gdansk extractme kit (EM09.1) according to the manufacturers protocol. cDNA was prepared from whole RNA samples using the RevertAid cDNA kit from Thermo Fisher (K1621). qRT-PCR for *Aicda*, *Spi1* and *Pax5* was performed using the SybrGreen MasterMix reagent (4385612, AppliedBiosystems) in a StepOnePlus cycler (AppliedBiosystems). Data presented as percentage of HPRT using the formula $x = 1 / 2^{(\text{cycles}_{Aicda} - \text{cycles}_{HPRT})} * 100$.

***In vivo* therapeutic studies and ultrasound imaging**

Mice were injected with 3×10^5 T8.1 cells intraperitoneally and monitored daily for clinical symptoms. When mice began showing signs of general morbidity, leukemia was confirmed by FACS analysis of tail vein blood for B220⁺ mIgM⁺ blast cells. When blast cells in pB reached 25 (mean 50) %, therapy was initiated with oral Dexamethasone (Jenapharm) at 6 mg/L supplied *ad libitum* in the drinking water for seven days. Maintenance therapy comprised either Ruxolitinib phosphate (S5243, Sellekchem) 1 mg (in 2% DMSO, 30% PEG300 in H₂O, as proposed by the manufacturer), Defactinib (S7654, Sellekchem) 1.2 mg (in 5 % DMSO, 50 % PEG300, 5 % Tween 80 in H₂O, as proposed by the manufacturer) or vehicle control (5 % DMSO, 50 % PEG300, 5 % Tween 80 in H₂O) administered twice daily via oral gavage. During the course of disease, this treatment led to paraparesis of the hind legs and tail. A clinical scoring system was established according to the extent of paraparesis and mice were scored daily accordingly: Scores 0-3: 0) no paraparesis, 1) paraparesis induced by treatment intervention, resolves within 30 s, 2) paraparesis induced by treatment intervention, does not resolve within 30 s, 3) persistent paraparesis, independent of treatment intervention. Score 3 prompted sacrifice of affected mice. High-resolution ultrasound imaging was performed using a Visual Sonics Vevo 2100 System (FUJIFILM VisualSonics, Toronto, Canada) with microscan transducer MS-550-D, 22-55MHz (FUJIFILM VisualSonics, Toronto, Canada) as described previously.⁷⁶

Data availability

The RNAseq datasets generated during the current study have been deposited in the Gene Expression Omnibus (GEO) archive and are available under the accession number GSE192424. The WES datasets can be accessed under PRJNA706650 in the sequencing read archive (SRA).

636 **Statistical analysis**

637 Statistical analysis was performed using the GraphPad 9.0 software. Data are commonly
 638 presented as mean $\pm$ SD. Prior to significance testing, normal distribution and homogeneity of
 639 variances was confirmed by Shapiro–Wilk test and Brown–Forsythe testing. Statistical
 640 significance when comparing two normally distributed groups was evaluated using two-tailed
 641 unpaired t-tests. In case of significant differences in variances between groups, Welch's
 642 correction was applied to account for non-normal distribution of data. When comparing
 643 multiple groups, one-way or two-way analysis of variance (ANOVA) was performed, depending
 644 on the number of variables that differed between compared groups. This was followed by a
 645 Tukey's Sidak, or Dunnett's *post hoc* test, as indicated in figure legends. An alpha level of $P <$
 646 0.05 was employed for significance testing.

647

648 **Study approval**

649 All animal experiments were approved by the local government (Regierungspräsidium Gießen,
 650 G49/2018, G34/2021) and conducted according to the German animal protection law.

651

652 Primers

Sanger Sequencing	
mJAK3 for	5' CCCGTCCTGCTGTGCGCTGACAC 3'
mJAK3 rev	5' GGAATCGGGATGCCAGGTGTGG 3'
mJAK3 mid part	5' CGATGTCTGGAGTCCATGACCTTCAG 3'
Mutagenesis / Cloning	
mJAK3 T844M for	5' CCCCCTGGGGGACAATATGGGACCCCT 3'
mJAK3 T844M rev	5' AGGGGTCCCATATTGTCCCCCAGGGGG 3'
mJAK3 R653H for	5' ATCACCCCCCTCATGAGCCAGGAGCAC 3'
mJAK3 R653H rev	5' GTGCTCCTGGCTCATGAGGGGGGTGAT 3'
mJAK3 for <i>Bam</i> HI	5' AAAGGATCCATGGCACCTCCAAGTGAGGAGACACCTC 3'
mJAK3 for <i>Sall</i>	5' AAAAGTCGACTATCCGGGTCTTCCACGCCACAGC 3'
V μ H clonality PCR	
V μ H for	5' GTGCTGGGCAGGAAGTCCCG 3'
V μ H rev	5' AGGTSMARCTGCAGSAGTCWGG 3' *
qRT-PCR	
<i>Pax5</i> fwd	5' CAAGCCAGAACAGACCACAGA 3'
<i>Pax5</i> rev	5' GGCCTGTGACAATAGGGTAGG 3'
<i>Spi1</i> fwd	5' ATCAAACCTTGTCCCCAGCC 3'
<i>Spi1</i> rev	5' TTTTCTTGCTGCCTGTCTCC 3'
<i>Aicda</i> fwd	5' AAATGTCCGCTGGGCCAA 3'
<i>Aicda</i> rev	5' CATCGACTTCGTACAAGGG 3'
<i>Aicda</i> (2) fwd	5'AGTCACGCTGGAGACCGATA 3'
<i>Aicda</i> (2) rev	5' GCAGAGGTAGGTCTCATGCC 3'

653

654 *: V μ H rev represents a mixture of different primers according to a degenerate nucleotide code,

655 for amplification of more V μ H sequences. S: C/G, M: A/C, R: A/G, W: A/T

656 **Author contributions**

657 D.D.G., C.P., N.S., M.B., F.H., M.L. designed experiments; D.D.G., C.P., N.S., M.B., D.S.,
 658 L.M., B.C., F.H. performed experiments; D.D.G., C.P., M.B., H.R., E.R., P.D., M.W., M.M.,
 659 A.N., U.M.B., F.M., F.H., M.B., H.M.J., A.N., A.B., M.K., T.B., T.S., A.P. M.L. analyzed data;
 660 D.D.G. and M.L. prepared the manuscript.

661

662 **Acknowledgements**

663 The authors want to thank Koji Tokoyoda (DRFZ, Berlin) for supplying *Il7^{eGFP}* mice for breeding,
 664 Olli Silvennoinen (Tampere-university, Finland) for supplying us with the JAK3 construct and
 665 to Fritz Melchers (DRFZ Berlin) for the JIL-7.6 J558 and ST2 cells. Further, Hyun-Dong Chang
 666 and Anja Hauser (both DRFZ, Berlin) for supplying OP-9 cells and Kawamoto materials
 667 respectively. D.D.G. received personal funding through the German Cancer Aid, Mildred-
 668 Scheel doctoral scholarship (70112922). M.L. was funded by the Deutsche
 669 Forschungsgemeinschaft (DFG) (LO 396/8-1) and the Else Kröner-Fresenius-Stiftung.

670 **References**

- 671 1 Johnson K, Hashimshony T, Sawai CM, Pongubala JMR, Skok JA, Aifantis I *et al.* Regulation of
672 immunoglobulin light-chain recombination by the transcription factor IRF-4 and the attenuation of
673 interleukin-7 signaling. *Immunity* 2008; **28**: 335–45.

- 674 2 Geier JK, Schlissel MS. Pre-BCR signals and the control of Ig gene rearrangements. *Semin*
675 *Immunol* 2006; **18**: 31–39.

- 676 3 Herzog S, Reth M, Jumaa H. Regulation of B-cell proliferation and differentiation by pre-B-cell
677 receptor signalling. *Nat Rev Immunol* 2009; **9**: 195–205.

- 678 4 Fistonich C, Zehentmeier S, Bednarski JJ, Miao R, Schjerven H, Sleckman BP *et al.* Cell circuits
679 between B cell progenitors and IL-7+ mesenchymal progenitor cells control B cell developmentCell
680 circuits control B cell development. *J Exp Medicine* 2018; **215**: 2586–2599.

- 681 5 Huber M, Lohoff M. IRF4 at the crossroads of effector T-cell fate decision. *Eur J Immunol* 2014; **44**:
682 1886–1895.

- 683 6 Lohoff M, Mak TW. Roles of interferon-regulatory factors in T-helper-cell differentiation. *Nat Rev*
684 *Immunol* 2005; **5**: 125–135.

- 685 7 Mittrücker H-W, Matsuyama T, Grossman A, Kündig TM, Potter J, Shahinian A *et al.* Requirement
686 for the Transcription Factor LSIRF/IRF4 for Mature B and T Lymphocyte Function. *Science* 1997; **275**:
687 540–543.

- 688 8 Lu R, Medina KL, Lancki DW, Singh H. IRF-4,8 orchestrate the pre-B-to-B transition in lymphocyte
689 development. *Gene Dev* 2003; **17**: 1703–1708.

- 690 9 Katz AJ, Chia VM, Schoonen WM, Kelsh MA. Acute lymphoblastic leukemia: an assessment of
691 international incidence, survival, and disease burden. *Cancer Cause Control* 2015; **26**: 1627–1642.

692 10 Gale KB, Ford AM, Repp R, Borkhardt A, Keller C, Eden OB *et al.* Backtracking leukemia to birth:
693 Identification of clonotypic gene fusion sequences in neonatal blood spots. *Proc National Acad Sci*
694 1997; **94**: 13950–13954.

695 11 Tasian SK, Hurtz C, Wertheim GB, Bailey NG, Lim MS, Harvey RC *et al.* High incidence of
696 Philadelphia chromosome-like acute lymphoblastic leukemia in older adults with B-ALL. *Leukemia*
697 2016; **31**: 981–984.

698 12 Roberts KG. Genetics and prognosis of ALL in children vs adults. *Hematology Am Soc Hematology*
699 *Educ Program* 2018; **2018**: 137–145.

700 13 Mullighan CG. Genomic Characterization of Childhood Acute Lymphoblastic Leukemia. *Semin*
701 *Hematol* 2013; **50**: 314–324.

702 14 Liu Y-F, Wang B-Y, Zhang W-N, Huang J-Y, Li B-S, Zhang M *et al.* Genomic Profiling of Adult and
703 Pediatric B-cell Acute Lymphoblastic Leukemia. *Ebiomedicine* 2016; **8**: 173–83.

704 15 Harvey RC, Kang H, Roberts KG, Chen I-ML, Atlas SR, Bedrick EJ *et al.* Development and
705 Validation Of a Highly Sensitive and Specific Gene Expression Classifier To Prospectively Screen and
706 Identify B-Precursor Acute Lymphoblastic Leukemia (ALL) Patients With a Philadelphia Chromosome-
707 Like (“Ph-like” or “BCR-ABL1-Like”) Signature For Therapeutic Targeting and Clinical Intervention.
708 *Blood* 2013; **122**: 826–826.

709 16 Mullighan CG, Su X, Zhang J, Radtke I, Phillips LAA, Miller CB *et al.* Deletion of IKZF1 and
710 Prognosis in Acute Lymphoblastic Leukemia. *New Engl J Medicine* 2009; **360**: 470–480.

711 17 Boer MLD, Slegtenhorst M van, Menezes RXD, Cheok MH, Buijs-Gladdines JG, Peters ST *et al.* A
712 subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide
713 classification study. *Lancet Oncol* 2009; **10**: 125–134.

714 18 Boer JM, Marchante JRM, Evans WE, Horstmann MA, Escherich G, Pieters R *et al.* BCR-ABL1-like
715 cases in pediatric acute lymphoblastic leukemia: a comparison between DCOG/Erasmus MC and
716 COG/St. Jude signatures. *Haematologica* 2015; **100**: e354–e357.

717 19 Roberts KG, Li Y, Payne-Turner D, Harvey RC, Yang Y-L, Pei D *et al.* Targetable kinase-activating
718 lesions in Ph-like acute lymphoblastic leukemia. *New Engl J Medicine* 2014; **371**: 1005–15.

719 20 Jo S-H, Schatz JH, Acquaviva J, Singh H, Ren R. Cooperation between deficiencies of IRF-4 and
720 IRF-8 promotes both myeloid and lymphoid tumorigenesis. *Blood* 2010; **116**: 2759–67.

721 21 Hardy RR, Carmack CE, Shinton SA, Kemp JD, Hayakawa K. Resolution and characterization of
722 pro-B and pre-pro-B cell stages in normal mouse bone marrow. *J Exp Medicine* 1991; **173**: 1213–
723 1225.

724 22 Sen J, Arceci RJ, Jones W, Burakoff SJ. Expression and ontogeny of murine CD2. *Eur J Immunol*
725 1989; **19**: 1297–1302.

726 23 Zehentmeier S, Pereira JP. Cell circuits and niches controlling B cell development. *Immunol Rev*
727 2019; **289**: 142–157.

728 24 Tokoyoda K, Egawa T, Sugiyama T, Choi B-I, Nagasawa T. Cellular Niches Controlling B
729 Lymphocyte Behavior within Bone Marrow during Development. *Immunity* 2004; **20**: 707–718.

730 25 Ma Q, Jones D, Springer TA. The Chemokine Receptor CXCR4 Is Required for the Retention of B
731 Lineage and Granulocytic Precursors within the Bone Marrow Microenvironment. *Immunity* 1999; **10**:
732 463–471.

733 26 Batista CR, Lim M, Laramée A-S, Abu-Sardanah F, Xu LS, Hossain R *et al.* Driver mutations in
734 Janus kinases in a mouse model of B-cell leukemia induced by deletion of PU.1 and Spi-B. *Blood Adv*
735 2018; **2**: 2798–2810.

736 27 Refsland EW, Harris RS. The APOBEC3 family of retroelement restriction factors. *Curr Top*
737 *Microbiol* 2013; **371**: 1–27.

738 28 Petersen-Mahrt SK, Harris RS, Neuberger MS. AID mutates E. coli suggesting a DNA deamination
739 mechanism for antibody diversification. *Nature* 2002; **418**: 99–104.

740 29 Noia JD, Neuberger MS. Altering the pathway of immunoglobulin hypermutation by inhibiting uracil-
741 DNA glycosylase. *Nature* 2002; **419**: 43–48.

742 30 Wilson TM, Vaisman A, Martomo SA, Sullivan P, Lan L, Hanaoka F *et al.* MSH2–MSH6 stimulates
743 DNA polymerase η , suggesting a role for A:T mutations in antibody genes. *J Exp Med* 2005; **201**:
744 637–645.

745 31 Swaminathan S, Klemm L, Park E, Papaemmanuil E, Ford A, Kweon S-M *et al.* Mechanisms of
746 clonal evolution in childhood acute lymphoblastic leukemia. *Nat Immunol* 2015; **16**: 766–74.

747 32 Malard F, Mohty M. Acute lymphoblastic leukaemia. *Lancet* 2020; **395**: 1146–1162.

748 33 Mullighan CG. How advanced are we in targeting novel subtypes of ALL? *Best Pract Res Cl Ha*
749 2019; **32**: 101095.

750 34 Bastian L, Schroeder MP, Eckert C, Schlee C, Sanchez JO, Kämpf S *et al.* PAX5 biallelic genomic
751 alterations define a novel subgroup of B-cell precursor acute lymphoblastic leukemia. *Leukemia* 2019;
752 **33**: 1895–1909.

753 35 Jain N, Roberts KG, Jabbour E, Patel K, Eterovic AK, Chen K *et al.* Ph-like acute lymphoblastic
754 leukemia: a high-risk subtype in adults. *Blood* 2017; **129**: 572–581.

755 36 Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O *et al.* Highly accurate protein
756 structure prediction with AlphaFold. *Nature* 2021; **596**: 583–589.

757 37 Herold T, Schneider S, Metzeler K, Neumann M, Hartmann L, Roberts KG *et al.* Philadelphia
758 chromosome-like acute lymphoblastic leukemia in adults have frequent IGH-CRLF2 and JAK2
759 mutations, persistence of minimal residual disease and poor prognosis. *Haematologica* 2016; **102**:
760 haematol.2015.136366.

761 38 Corfe SA, Paige CJ. The many roles of IL-7 in B cell development; Mediator of survival,
762 proliferation and differentiation. *Semin Immunol* 2012; **24**: 198–208.

763 39 Milford TM, Su RJ, Francis OL, Baez I, Martinez SR, Coats JS *et al.* TSLP or IL-7 provide an IL-
764 7Ra signal that is critical for human B lymphopoiesis. *Eur J Immunol* 2016; **46**: 2155–2161.

765 40 Verbeke D, Gielen O, Jacobs K, Boeckx N, Keersmaecker KD, Maertens J *et al.* Ruxolitinib
766 Synergizes With Dexamethasone for the Treatment of T-cell Acute Lymphoblastic Leukemia.
767 *Hemasphere* 2019; **3**: e310.

768 41 Härzschel A, Zucchetto A, Gattei V, Hartmann TN. VLA-4 Expression and Activation in B Cell
769 Malignancies: Functional and Clinical Aspects. *Int J Mol Sci* 2020; **21**: 2206.

770 42 Springer TA. Adhesion receptors of the immune system. *Nature* 1990; **346**: 425–434.

771 43 Tijchon E, Havinga J, Leeuwen FN van, Scheijen B. B-lineage transcription factors and cooperating
772 gene lesions required for leukemia development. *Leukemia* 2013; **27**: 541–552.

773 44 Martin-Lorenzo A, Hauer J, Vicente-Duenas C, Auer F, Gonzalez-Herrero I, Garcia-Ramirez I *et al.*
774 Infection Exposure Is a Causal Factor in B-cell Precursor Acute Lymphoblastic Leukemia as a Result
775 of Pax5-Inherited Susceptibility. *Cancer Discov* 2015; **5**: 1328–1343.

776 45 Schjerven H, Ayongaba EF, Aghajani-refah A, McLaughlin J, Cheng D, Geng H *et al.* Genetic
777 analysis of Ikaros target genes and tumor suppressor function in BCR-ABL1+ pre-B ALL. Ikaros tumor
778 suppressor function in Ph+ pre-B ALL. *J Exp Medicine* 2017; **214**: 793–814.

779 46 Pang SHM, Minnich M, Gangatirkar P, Zheng Z, Ebert A, Song G *et al.* PU.1 cooperates with IRF4
780 and IRF8 to suppress pre-B-cell leukemia. *Leukemia* 2016; **30**: 1375–1387.

781 47 Vicente-Dueñas C, Janssen S, Oldenburg M, Auer F, González-Herrero I, Casado-García A *et al.*
782 An intact gut microbiome protects genetically predisposed mice against leukemia. *Blood* 2020; **136**:
783 2003–2017.

784 48 Lupardus PJ, Ultsch M, Wallweber H, Kohli PB, Johnson AR, Eigenbrot C. Structure of the
785 pseudokinase–kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK)
786 autoinhibition. *Proc National Acad Sci* 2014; **111**: 8025–8030.

787 49 McElroy CA, Holland PJ, Zhao P, Lim J-M, Wells L, Eisenstein E *et al.* Structural reorganization of
788 the interleukin-7 signaling complex. *Proc National Acad Sci* 2012; **109**: 2503–2508.

789 50 Thomas KR, Allenspach EJ, Camp ND, Wray-Dutra MN, Khim S, Zielinska-Kwiatkowska A *et al.*
790 Activated interleukin-7 receptor signaling drives B-cell acute lymphoblastic leukemia in mice.
791 *Leukemia* 2021; : 1–16.

792 51 Hertzberg L, Vendramini E, Ganmore I, Cazzaniga G, Schmitz M, Chalker J *et al.* Down syndrome
793 acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2
794 is associated with mutated JAK2: a report from the International BFM Study Group. *Blood* 2010; **115**:
795 1006–1017.

796 52 Tasian SK, Assad A, Hunter DS, Du Y, Loh ML. A Phase 2 Study of Ruxolitinib with Chemotherapy
797 in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (INCB18424-
798 269/AALL1521): Dose-Finding Results from the Part 1 Safety Phase. *Blood* 2018; **132**: 555–555.

799 53 Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF *et al.* A double-blind, placebo-
800 controlled trial of ruxolitinib for myelofibrosis. *New Engl J Medicine* 2012; **366**: 799–807.

801 54 Appelmann I, Rillahan CD, Stanchina E de, Carbonetti G, Chen C, Lowe SW *et al.* Janus kinase
802 inhibition by ruxolitinib extends dasatinib- and dexamethasone-induced remissions in a mouse model
803 of Ph+ ALL. *Blood* 2014; **125**: 1444–51.

804 55 Hara T, Shitara S, Imai K, Miyachi H, Kitano S, Yao H *et al.* Identification of IL-7–Producing Cells in
805 Primary and Secondary Lymphoid Organs Using IL-7–GFP Knock-In Mice. *J Immunol* 2012; **189**:
806 1577–1584.

807 56 Ogawa M, Nishikawa S, Ikuta K, Yamamura F, Naito M, Takahashi K *et al.* B cell ontogeny in
808 murine embryo studied by a culture system with the monolayer of a stromal cell clone, ST2: B cell
809 progenitor develops first in the embryonal body rather than in the yolk sac. *Embo J* 1988; **7**: 1337–43.

810 57 Ceredig R, Boekel E ten, Rolink A, Melchers F, Andersson J. Fetal liver organ cultures allow the
811 proliferative expansion of pre-B receptor-expressing pre-B-II cells and the differentiation of immature
812 and mature B cells in vitro. *Int Immunol* 1998; **10**: 49–59.

813 58 Kang CH, Hartmann E, Menke L, Staudenraus D, Abass E-F, Raifer H *et al*. A hyperactive mutant
814 of interferon-regulatory factor 4. *Eur J Immunol* 2018; **49**: 812–815.

815 59 Maaten LVD, Hinton G. Visualizing data using t-SNE. *J Mach Learn Res* 2008; : 2579–2625.

816 60 Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. *Nat Methods* 2012; **9**: 357–
817 9.

818 61 Klambauer G, Schwarzbauer K, Mayr A, Clevert D-A, Mitterecker A, Bodenhofer U *et al*. cn.MOPS:
819 mixture of Poissons for discovering copy number variations in next-generation sequencing data with a
820 low false discovery rate. *Nucleic Acids Res* 2012; **40**: e69.

821 62 Kawamoto T. Use of a new adhesive film for the preparation of multi-purpose fresh-frozen sections
822 from hard tissues, whole-animals, insects and plants. *Arch Histol Cytol* 2003; **66**: 123–143.

823 63 Zehentmeier S, Roth K, Cseresnyes Z, Sercan Ö, Horn K, Niesner RA *et al*. Static and dynamic
824 components synergize to form a stable survival niche for bone marrow plasma cells. *Eur J Immunol*
825 2014; **44**: 2306–2317.

826 64 Canene-Adams K. Preparation of formalin-fixed paraffin-embedded tissue for
827 immunohistochemistry. *Methods Enzymol* 2013; **533**: 225–33.

828 65 Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T *et al*. Fiji: an open-
829 source platform for biological-image analysis. *Nat Methods* 2012; **9**: 676–682.

830 66 Li H, Durbin R. Fast and accurate short read alignment with Burrows–Wheeler transform.
831 *Bioinformatics* 2009; **25**: 1754–1760.

832 67 McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytzsky A *et al.* The Genome
833 Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data.
834 *Genome Res* 2010; **20**: 1297–1303.

835 68 Brochet X, Lefranc M-P, Giudicelli V. IMGT/V-QUEST: the highly customized and integrated
836 system for IG and TR standardized V-J and V-D-J sequence analysis. *Nucleic Acids Res* 2008; **36**:
837 W503-8.

838 69 Zhu J, Cote-Sierra J, Guo L, Paul WE. Stat5 Activation Plays a Critical Role in Th2 Differentiation.
839 *Immunity* 2003; **19**: 739–748.

840 70 Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning
841 sequence reads to genomic features. *Bioinformatics* 2014; **30**: 923–930.

842 71 Marini F, Binder H. pcaExplorer: an R/Bioconductor package for interacting with RNA-seq principal
843 components. *Bmc Bioinformatics* 2019; **20**: 331.

844 72 Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq
845 data with DESeq2. *Genome Biol* 2014; **15**: 550.

846 73 Marini F, Ludt A, Linke J, Strauch K. GeneTonic: an R/Bioconductor package for streamlining the
847 interpretation of RNA-seq data. *Biorxiv* 2021; : 2021.05.19.444862.

848 74 Varadi M, Anyango S, Deshpande M, Nair S, Natassia C, Yordanova G *et al.* AlphaFold Protein
849 Structure Database: massively expanding the structural coverage of protein-sequence space with
850 high-accuracy models. *Nucleic Acids Res* 2021. doi:10.1093/nar/gkab1061.

851 75 Pettersen EF, Goddard TD, Huang CC, Meng EC, Couch GS, Croll TI *et al.* UCSF ChimeraX:
852 Structure visualization for researchers, educators, and developers. *Protein Sci* 2021; **30**: 70–82.

853 76 Buchholz SM, Goetze RG, Singh SK, Ammer-Herrmenau C, Richards FM, Jodrell DI *et al.* Depletion
854 of Macrophages Improves Therapeutic Response to Gemcitabine in Murine Pancreas Cancer. *Cancers*
855 2020; **12**: 1978.

Fig.1: Spontaneous emergence of preB-I cell BCP-ALL in adult *Irf4*^{-/-} mice

a A cohort of 80 *Irf4*^{-/-} and wt mice was observed over 500 days for tumour development. Kaplan-Meier plot of survival. Box and whisker plot indicates minimum, maximum and median age at tumour appearance of the 14 affected mice. **b** Macroscopic appearance of an exemplary tumour (asterisk) and LNs (arrow heads) in an *Irf4*^{-/-} mouse. Right: Hematoxylin-Eosin (HE) staining from the tumour. Scale bars: top: 50 μ m, bottom: 20 μ m **c** Longitudinal spleen (S) axis (mm) of *Irf4*^{-/-} mice with (n = 8) or without (n = 5) tumour and control wt mice (n = 6). tum = tumour **d** HE stainings of lung, liver and BM of tumour mouse T8 and a healthy *Irf4*^{-/-} mouse. Scale Bars: 50 μ m (lung and liver), 20 μ m (BM) **e** IHC-stainings of T8 mouse spleen for Ig μ , B220 and Ki67. Scale bars: 100 μ m **f** schematic representation of gross Hardy fractioning by surface B220 and Ig μ expression **g** whole BM cells from wt, *Irf4*^{-/-} and tumour mice were stained for B220 and slg μ expression and analyzed by flow cytometry **h** quantification of cell frequencies gated as in (g) for BM, S, LN and pB (peripheral blood) of n = 3 mice per group **i** tabular representation of Hardy fr.A-D by size, CD43-, CD24- and BP-1-surface expression **j** surface expression of markers as in (i) of *in vitro* cultured T8 tumour cells **k** quantification of cell frequencies gated as in (j) for three tumours (T8, T11, TD3) **l** surface λ 5 expression on T8, T11 and TD3 by flow cytometry in comparison to whole BM cells from *Irf4*^{-/-} mice (BM) as negative control. Statistical significance testing was performed with (c) one-way Welch-ANOVA followed by Dunnet's T3 multiple comparison test and (h) with two-way ANOVA followed by pair-wise Tukey corrected comparisons within each organ. Bars depict mean $\pm$ SD, dots indicate mice (h) or distinct *Irf4*^{-/-} tumours (k)

Fig.2: *lrf4*^{-/-} B lymphopoiesis is preleukemically altered

a-c flow cytometric analysis of BM cells for Hardy markers as in Fig.1j. **a** tSNE of BM cells gated on B220⁺ cells. Colours correspond to Hardy fractions identified by the markers detailed in the legend. **b** and **c** quantification of Hardy fraction frequencies for n = 3 mice per genotype.

d-h BM cells from *lrf4*^{-/-} and wt mice were cultured in the presence of 10 ng/mL rmlL-7 for 6 days and **d** counted every two days. **e-f** After 4 days, cells were stained as in (**a-c**) and Hardy fractions quantified. **g** frequency and **h** absolute cell counts of λ5⁺ cells on day 4. **i** spleen cells from *lrf4*^{-/-} and wt mice were analyzed for presence of CD2^{-dim}slgμ⁻ cells within the B220⁺ gate. (y = young) one-way ANOVA, Tukey post-hoc **j-m** 7 μm cryosections from *lrf4*^{-/-}*Il7*^{eGFP} and wt *Il7*^{eGFP} mice were stained for B220, CD2, GFP and DAPI. **j** exemplary regions of BM cryosections. Arrowheads indicate B220⁺CD2^{-dim} cells. Scale bars = 15 μm. **k** automated B220⁺ cell detection: grey spheres indicate B220⁺ cells, larger spheres B220⁺CD2^{-dim} cells, colour-coded for their distance to GFP⁺ cells. Rectangles indicate magnified areas in (**j**). Scale bars = 40 μm. **l-m** quantification of distances to IL-7⁺ cells for **l** all B220⁺ and **m** B220⁺CD2^{-dim} cells. (n = 4 mice per genotype, one cryosection from femur metaphysis per mouse analyzed). Box and whiskers indicate mean and 95-IQR, dots indicate cells outside 95-IQR. **n** BM cells from *lrf4*^{-/-} and wt mice were gated on B220⁺slgμ⁻ fr.A-D cells and analyzed for CXCR4 expression (left panels as representative staining). Data is presented for n = 7 (wt) and n = 6 (*lrf4*^{-/-}) mice as the ratio of geometric mean for CXCR4 to isotype staining.) **o** MACS-purified fr.A-D cells from BM were placed in the top insert of a Boyden chamber and left to migrate towards differing concentrations of CXCL12 for 16 h. Dots represent n = 4 biologically independent experiments, presented as migrated percentage of input cells. Two-Way Anova, Sidak post-hoc for (**b-c**, **e-f**, **o**), Two-tailed unpaired t-test for (**g-h**, **l-n**)

Fig.3: leukemia derived *Jak3* mutations heighten IL-7 sensitivity of *Irfa*^{-/-} preB-I cells

a Venn diagram of shared mutated genes among WES from three *Irfa*^{-/-} leukemia samples (T8, T10, T11) **b** the nine shared genes were filtered for SNV frequency. grey areas: > 0.95 and 0.45-0.55 margins as core mutation filters. **c** the five detected distinct *Jak3* SNVs were mapped onto JAK3 primary structure (JH = Jak homology domain). **d** *Irfa*^{-/-} leukemia WES were analyzed for mutations (SNV or InDel = insertions/deletions) in genes commonly altered in human BCP-ALL. Numbers indicate rounded frequencies of alteration. **e-k** *Irfa*^{-/-} BM cells were cultured for 6 d with 10 ng/mL rmlL-7, transduced with control or **(e-g)** JAK3_{mut} coding or **(h-k)** STAT5ca coding RVs, rested for 2 days and then split into decreasing IL-7 concentrations. **f** histograms for the Thy1.1 RV infection marker 6 days after splitting. **g** Quantification of Thy1.1⁺ cells after 6 days relative to start of culture (t = 0). Dots indicate n = 3 independent experiments, plotted as floating bars. EV = empty vector. **h** qRT-PCR from wt and *Irfa*^{-/-} cells for *Aicda* mRNA expression, relative to *Hprt* expression for n = 3 (Th (= T helper) and sorted fr.A-D wt BM cells), n = 5 (mLN (= mesenteric lymph node) and sorted fr.A-D *Irfa*^{-/-} BM cells), n = 1 per tumour T8, T11, T27. **i** *Irfa*^{-/-} preB-I cell cultures from whole BM cells were cultured in combinations of IL-7, αIL-7 and LPS for 24 h, as indicated, and analyzed for *Aicda* levels by qRT-PCR for n = 4 (no LPS) and n = 3 (LPS) samples. **j** WES from fr.A-D cells and T8 were compared to tail tip samples to identify SNVs. Filtering on SNV frequency “0.45-0.55 or ≥ 0.95” yielded putative “core mutations”. Absolute numbers of nucleotide exchanges are presented as stacked bars, colours give the type of nucleotide exchange. Two-way ANOVA, Sidak post-hoc for **(h-i)**, One-way ANOVA, Tukey post-hoc for **(l-m)**

922 **Fig.4: *Jak3* mutations heighten IL-7 sensitivity in *lrf4*^{-/-} BCP-ALL**

923 **a** cartoon depicting IL-7 and TSLP receptor components. **b** multiple sequence alignment
924 results (using Clustal Omega) of mouse (m) and human (h) JAK3 and JAK2 amino-acid
925 sequences are presented as matrix. Numbers and shade indicate sequence identity as
926 percentage of amino-acids. **c-d** alpha-fold structure predictions of murine **c** JAK3 and **d** JAK2
927 are presented. Colours indicate domains: orange = JH1, blue = JH2. JH1-JH2 interface is
928 magnified and T844/T875, R653/R683, D842/D873 amino-acids highlighted as ball-and-sticks
929 representations. Dotted lines = hydrogen bonds. **e** overview of analysis for **f**: Sequences of
930 mJAK2 and mJAK3 were aligned using Clustal Omega. The sequence of mJAK3 was binned
931 into 10 non-overlapping amino-acid fragments and the sequence identity to mJAK2 plotted
932 along the mJAK3 sequence. Dotted line = mean protein wide sequence identity, black bars =
933 areas with sequence identity greater than 1 SD above mean. JH1 and JH2 loop regions are
934 mapped onto the sequence, JH1 and JH2 domain regions indicated by coloured rectangles
935 below. **g-j** *lrf4*^{-/-} BM cells were cultured for 6 days in the presence of 10 ng/mL rmIL-7, 10 or
936 100 ng/mL rmTSLP_(lo/hi) or no cytokine (none). **g** log₂ of cell counts relative to day 0 for n = 3
937 independent experiments plotted as means ± SD. One-way ANOVA, Sidak post-hoc
938 comparing cytokine effect **h-i** On day 4, **h** CD43⁺ and **i** λ5⁺ cells within B220⁺ cells were
939 recorded for IL-7 and TSLP treated cultures. Numbers indicate percentages within the depicted
940 gates of B220⁺ cells. **j** absolute counts of λ5⁺ cells at day 4. Dots in (**h-j**) indicate n = 3
941 independent experiments, presented as bars (mean ± SD). Unpaired two-tailed t-test for (**h-j**)
942

943 **Fig.5: IRF4 re-expression results in apoptosis and differentiation of leukemia cells**

944 **a-c** T8 and T11 cells were transduced with IRF4-RV or control empty vector (EV)-RV. **a** GFP⁺

945 cell frequency normalized to 24 h after transduction was recorded. One-Way ANOVA, Sidak

946 post-hoc for RV effect per tumour. Mean $\pm$ SD of n = 3 independent experiments. **b**

947 representative histogram of $\lambda 5$ surface expression of GFP⁺ cells at 48 h. **c** Pooled

948 Quantification of $\lambda 5^{\text{Hi}}$ cells for three (24, 72h) to five (48h) independent experiments for T8 and

949 T11. **d-h** T8 cells were collected in duplicates at 24 h after EV-RV and IRF4-RV transduction

950 and subjected to bulk RNAseq. **d** MDS plot of top 100 gene ontology (GO) gene-sets varying

951 between EV and IRF4 transduced T8. Representative gene-sets annotated. Size of circles =

952 number of genes, colour = z score. **e** analysis strategy for GO gene-set clustering using Markov

953 clustering. **f** gene-sets from Markov cluster 3 and corresponding P values and z scores. **g**

954 volcano plot of B cell genes from Markov cluster 3 (red) highlighted within all differentially

955 regulated genes (black). **h** heat map of B cell receptor signaling GO gene-sets.

956 Immunoglobulin genes and the tumour suppressor *Blnk* are marked. Colour = z score.

Fig.6: Ruxolitinib reduces leukemic meningeosis and organ infiltration *in vivo*

a schematic overview of experimental design. Day 0: injection of mice with 2×10^5 T8 cells. After 12 days initiation of Dexamethasone induction therapy supplied in drinking water for seven days. Maintenance therapy comprised either Ruxolitinib-phosphate (11 mice) or vehicle control gavage (13 mice) twice daily for 14 days. Mice were scored daily and blood sampling performed regularly. **b** leukemia cell frequency ($B220^{+}slg\mu^{-}$) within lymphocyte gate before and after induction with Dexamethasone. Two-tailed unpaired t-test **c** time-course of leukemia cell frequencies in peripheral blood for Ruxolitinib and vehicle treated mice. **d** Survival as Kaplan-Meier plot analyzed with Log-rank test. In the Ruxolitinib group, 4 mice were excluded and censored due to intervention related adverse reactions or due to their use for to the analysis described in (f-i). **e** Disease scores, determined as described in methods. Mean $\pm$ SD of the scores per indicated treatment group analyzed by two-way ANOVA, Sidak post-hoc. $n = 2$ replicate experiments for (b-e) with similar outcome. **f** Exemplary histopathology (HE) of healthy or leukemia bearing mice (score 3, vehicle-treated or score 0, Ruxolitinib-treated). One representative mouse per condition. Bar size in the bottom right corners. Top panels: overview of cross-sectioned lumbar vertebra, bottom inserts from spinal canal (left) and spinal nerve root (right). **g** Schematic representation of calculation of tumour infiltration into the spinal canal. (A_t : area of tumour infiltration, A_{sca} : area of total spinal canal, A_{sp} : area of the spinal cord) **h** Quantification of spinal canal infiltration according to (g) for $n = 8$ after induction (baseline), $n = 3$ score 0 (Ruxolitinib) and $n = 4$ score 3 (vehicle) mice. **i** Representative CAE stainings from vertebral BM for score 0 and score 3 mice. **j** Quantification of area occupied by CAE⁺ cells relative to total BM area for $n = 4$ (baseline), $n = 3$ (score 0, Ruxolitinib) and $n = 4$ (score 3, vehicle) mice. **k** Representative HE stainings from liver tissue for score 0 and score 3 mice, Scale bar bottom right. **l** Quantification of tumour infiltrated area relative to whole liver area for

982 n = 5 (baseline), n = 3 (score 0, Ruxolitinib) and n = 4 (score 3, vehicle) mice. Each dot
983 represents measurements of three complete liver cross-sections per mouse.

984 **Fig.7: Summary of the preB-I preleukemic state induced by IRF4 deficiency**

985 Cartoon summarizing the findings for IRF4 deficient compared to wt B lymphopoiesis. B
 986 lineage (lin) cells are less responsive to BMSC derived CXCL12 due to reduced surface
 987 CXCR4 expression (1). *Irf4*^{-/-} preB-I cells exhibit impaired differentiation and IL-7 dependent
 988 hyperproliferation (2). *Irf4*^{-/-} preB cells escape into the periphery (3), where a combination of
 989 IL-7 deprivation and danger associated molecular patterns (such as LPS) might induce AID
 990 expression (4), fueling mutagenesis.

Fig.8: A “two-equilibrium model” explains JAK mutant effects in primary preB-I cells

a Equilibrium 1 is determined by cytokine abundance and dictates the cytokine receptor state (bound vs. relaxed). **b** Equilibrium 2 is determined by the interaction strength between JH1 and JH2 domains in JAKs and dictates the JAK state (inhibited vs. active). **c** Equilibria 1 and 2 interact to create four possible states. Green lettering indicates a signaling favoring state. Green frame indicates the actively signaling state. **d** For high (left), low (middle) and no (right) cytokine in the presence or absence of JAK3 mutations, hypothetical probabilities of equilibria states as in (**c**) are presented. Size of rectangles signifies likelihood of state relative to others. Arrows indicate shifts of equilibria, red arrows indicate the effect of JAK mutations. Green rectangle = active signaling state (bound and active). Bars to the right of each panel indicate signal strength as a direct result of the two equilibria adjacent to it.